ARTICLE | Clinical News
FG-4592: Preliminary Phase II data
November 12, 2007 8:00 AM UTC
Preliminary data from the first cohort of 29 patients in a placebo-controlled, dose-escalation Phase II trial in 8 evaluable patients showed that doses of up to 120 mg of FG-4592 were well tolerated. ...